The objectives of the Protocol Review and Monitoring System (PRMS) are to implement a transdisciplinary scientific peer-review system that ensures internal oversight of the scientific quality and progress of clinical trials and optimally engages the institution's resources. The system ensures that clinical research trials at the USC Norris Comprehensive Cancer Center (NCCC) are of the highest scientific quality and integrity by review of the scientific merit, priorities and progress.
The specific aims of the PRMS are to: 1) maintain a Clinical Investigation Committee (CIC) with sufficient breadth of expertise to conduct an objective scientific and operational review of all clinical cancer research protocols;2) facilitate prompt initiation of approved protocols by interfacing with the IRB to ensure compliance with local and federal regulations;3) ensure and oversee a system of prioritization of clinical research protocols;4) monitor the scientific progress of clinical research protocols and ensure closure as required by interim analysis and stopping rules;5) terminate clinical research protocols that fail to meet expectations for scientific progress;6) review amendments for ongoing clinical research protocols;and 7) monitor compliance as well as gender and minority accrual in the conduct of clinical research protocols. The CIC is assisted by the Quality Assurance and Monitoring Committee (QAMC) in the monitoring of the progress of the studies. The QAMC fulfills multiple functions as detailed in the CISO section of the grant. In regards to PRMS, it provides the essential data regarding accrual and study conduct to the CIC, which allows the latter to perform its progress monitoring functions optimally.
As mandated by the Cancer Center, the Clinical Investigations Support Office provides essential assistance and support to investigators through the CIC and through the QAMC in order to ensure scientific quality and integrity starting with the initiation of each study and continuing to study completion.
|Lawrenson, Kate; Grun, Barbara; Lee, Nathan et al. (2015) NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer. Int J Cancer 136:1390-401|
|Milam, Joel E; Meeske, Kathleen; Slaughter, Rhona I et al. (2015) Cancer-related follow-up care among Hispanic and non-Hispanic childhood cancer survivors: The Project Forward study. Cancer 121:605-13|
|Maus, M K H; Hanna, D L; Stephens, C L et al. (2015) Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J 15:354-62|
|Hirsch, Louis; Nazari, Hossein; Sreekumar, Parameswaran G et al. (2015) TGF-?2 secretion from RPE decreases with polarization and becomes apically oriented. Cytokine 71:394-6|
|Chuh, Kelly N; Pratt, Matthew R (2015) Chemical methods for the proteome-wide identification of posttranslationally modified proteins. Curr Opin Chem Biol 24:27-37|
|Wu, Dai-Ying; Ou, Chen-Yin; Chodankar, Rajas et al. (2014) Distinct, genome-wide, gene-specific selectivity patterns of four glucocorticoid receptor coregulators. Nucl Recept Signal 12:e002|
|Zhang, Hongjun; Boddupally, Keerthi; Kandyba, Eve et al. (2014) Defining the localization and molecular characteristic of minor salivary gland label-retaining cells. Stem Cells 32:2267-77|
|Tai, Kenneth P; Le, Valerie V; Selsted, Michael E et al. (2014) Hydrophobic determinants of ?-defensin bactericidal activity. Infect Immun 82:2195-202|
|Su, Sheng-Fang; de Castro Abreu, André Luís; Chihara, Yoshitomo et al. (2014) A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res 20:1978-89|
|Challagundla, Kishore B; Fanini, Francesca; Vannini, Ivan et al. (2014) microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics. Expert Rev Mol Diagn 14:565-74|
Showing the most recent 10 out of 345 publications